Alkermes Posts $16.3 Million Third-Quarter Profit, Beating Loss Estimates
Key Facts
Alkermes reported on November 3 net income of $16.3 million, or 9 cents per share, for the quarter ended September 30, 2026. The result was above the estimates of five analysts surveyed by Zacks Investment Research, whose average forecast was a loss of 8 cents per share. The figures put the company ahead of prior earnings-per-share estimates. The company said it would hold a call to discuss the results and provide an update on its business that day. The call was scheduled for 8:00 a.m. Eastern Time, or 1:00 p.m. GMT.
Reported net income shows the accounting profit the company recorded during the quarter, while the 9-cent figure represents the share of that income attributable to each share. The comparison with Zacks estimates measures the result against the average forecasts of five analysts, not against earnings in the same period a year earlier. The average forecast pointed to a loss of 8 cents per share, making the shift to earnings of 9 cents a 17-cent-per-share difference between the forecast and the reported figure. This represents a clear beat of the estimate ahead of the report. The Zacks survey, as cited by the Associated Press, did not include forecasts for other results in this comparison.
On the stock’s performance, the Associated Press reported that Alkermes shares had risen 60% since the start of 2026 through November 3. They were also up 46% over the previous 12 months through the same date. These two percentages provide context for the stock’s performance over two periods and do not represent a change on the results-announcement session alone. According to EL7 data, the company’s shares closed at $44.89 on November 2, the session before the announcement date. The available figure for that session is limited to the closing price.
Alkermes completed its acquisition of Avadel Pharmaceuticals on February 12, 2026, and said in its announcement that the deal would accelerate its entry into the sleep-medicine market. The acquisition gives the company a presence in that market alongside its existing businesses, according to the company’s description of the deal. However, Alkermes listed the possibility that the two companies’ businesses may not be integrated effectively among its risk factors. It also warned that the anticipated benefits and value of the acquisition may not be realized. These risks put integration and delivery of the stated benefits among the issues the company is monitoring after completing the deal.
The company announced its third-quarter results on November 3 and scheduled an investor call for the same day to discuss the figures and provide an update on the company. According to the investor-relations announcement, the call was set for 8:00 a.m. Eastern Time, or 1:00 p.m. GMT. The call followed the announcement of net income of $16.3 million and earnings of 9 cents per share. It also gives investors an opportunity to follow the company’s discussion of the results at the announced time. The available evidence contained no subsequent figures on the call’s content or the stock’s movement after the announcement.